Trial Profile
Pivotal immunogenicity study of PF530 in patients with multiple sclerosis
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors Pelican Expression Technology
- 17 Mar 2016 New trial record
- 10 Mar 2016 According to Pfenex media release, company is planning to initiate this trial in 2H2016.